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BACKGROUND: The aims of this study were to compare human epidermal growth factor receptor 2 (HER2) results
between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), and to investigate the clinicopa-
thological characteristics and outcomes according to their results. METHODS: Using consecutive tissue microarrays,
IHC and FISH were performed as guidelines in 950 invasive breast cancers treated between November 1999 and Au-
gust 2005. Characteristics and outcomes were retrospectively analyzed using a chi-square test, the Kaplan-Meier
method, and Cox’s model. RESULTS: FISH-positivity was observed in 2.6%, 4.8%, 28.1%, and 93.8% of IHC 0, 1þ, 2þ,
and 3þ, respectively, and the concordance rate between the 2 assays was 95.5%. IHC-positive or FISH-positive cases
were associated with poorer differentiation, negative expression of hormone receptors, and higher proliferative index.
Among IHC-equivocal or IHC-negative patients, positive FISH was negatively associated with survival in univariate
and multivariate analyses. Among IHC-negative patients, tumors showing luminal B subtype features such as estro-
gen receptor (ER)-positive, grade II/III, and high Ki-67 presented discordantly high FISH-positivity. Among IHC-posi-
tive cases, FISH was not related to outcomes. CONCLUSIONS: The result of FISH is significantly related to prognosis
of patients with IHC-negative or IHC-equivocal result. Therefore, FISH should be performed in IHC-equivocal cases.
FISH assay might be considered for a selected group of patients with IHC-negative tumors showing luminal B sub-
type features of ER-positive, grade II/III, and high Ki-67 expression. Cancer 2012;118:914-23. VC 2011 American Cancer
Society.
KEYWORDS: breast cancer, fluorescence in situ hybridization, human epidermal growth factor receptor 2,
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Human epidermal growth factor receptor 2 (HER2) protein overexpression or gene amplification is found in 20% to
30% of breast cancers and is known to play important roles in the carcinogenesis and the prediction of clinical outcomes
and therapeutic responses.1-5 Among current several testing methods, immunohistochemistry (IHC) and fluorescence in
situ hybridization (FISH) are approved by the U.S. Food and Drug Administration and are the most commonly used for
assessing HER2 at many institutions. Both methods have complementary advantages and disadvantages.6,7 The advan-
tages of IHC are widely available, relatively inexpensive, quickly performed, easily preserved, and interpretable using light
microscope. FISH has the advantages of more objective and quantitative scoring system, being less influenced by preana-
lytic factors, and a built-in internal control.
Accurate determination of HER2 is critically relevant in the management of breast cancer patients, but clinical situa-
tions are more complex. Although FISH has shown high concordance rates with IHC because tumors without amplified
HER2 gene consistently did not present protein overexpression, a significant number of patients have demonstrated
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discrepant results between the 2 assays.6,8-12 The most dis-
cordant cases are those with IHC score of 2þ, and they
are now considered as equivocal result. When IHC is used
for the primary assessment of HER2, the current Ameri-
can Society of Clinical Oncology/College of American
Pathologists (ASCO/CAP) guidelines recommend IHC-
equivocal result be validated by FISH.9,13 FISH is not
mandatory for IHC-negative or IHC-positive cases.
Actually, HER2 protein, not the gene, is a definite
target for trastuzumab. Accurate prediction of response to
anti-HER2 therapy is one of clinical usages of HER2. Piv-
otal clinical trials using trastuzumab included metastatic
breast cancer patients with IHC-equivocal or IHC-posi-
tive result, and retrospective analyses demonstrated that
FISH is superior to IHC in selecting patients appropriate
for trastuzumab therapy.9,14 Even a small number of
IHC-negative or IHC-positive patients have been
reported to amplify HER2 gene or not by FISH, respec-
tively.8,11 Several questions regarding discordancies
between IHC and FISH remain to be determined. In this
study, we investigated the correlation between IHC and
FISH performed by current guidelines. If 2 assays of our
study are highly concordant as shown in previous studies,
it is assumed that discrepant results might be associated
with heterogeneous internal tumor-related features. The
aims of this study were to determine clinicopathological
characteristics and survival outcomes according to IHC
and FISH, and to explore whether FISH provides any
additional information in IHC-negative or IHC-positive
patients, and if so, to characterize patients who are likely
to benefit from FISH assay.
MATERIALS AND METHODS
Patient Selection
We had collected tumor specimens between November
1999 and August 2005. All 1153 samples were formalin-
fixed and paraffin-embedded. All archival hematoxylin
and eosin (H&E)-stained slides were reviewed by 2 path-
ologists. IHC and FISH were interpreted respectively in a
blinded fashion, without any information regarding clini-
cal parameters or outcomes. Among 1153 initial study
population, 203 cases were excluded for analyses; pure in
situ carcinoma (n¼ 38), recurrent or metastatic tumor (n
¼ 10), invasive tumors that did not present invasive focus
in the review of archival H&E-stained slides (n ¼ 89),
FISH-equivocal results (n ¼ 15), and unreadable HER2
assays due to insufficient invasive foci on the tissue micro-
array (TMA) slides, overlapping nuclei, or lacking signals
(n ¼ 51). As a result, 950 invasive breast cancer patients
were finally enrolled for analyses. Because most excluded
cases were in situ carcinomas and small tumors with
extensive intraductal components, excluded patients
showed earlier stage and well-differentiated tumor (data
not shown). This study was reviewed and approved by the
institutional review board of Severance Hospital, Yonsei
University Health System (4-2010-0136).
Data regarding patient characteristics and survival
were retrospectively obtained from medical records.
Patients were treated with either mastectomy or breast-
conserving surgery and sentinel lymph node biopsy or ax-
illary node dissection. After surgery, local radiotherapy or
adjuvant therapy was administered if patients were able to
tolerate it. Clinical follow-up included history taking,
physical examination, laboratory tests, and radiologic
imaging tests every 6-12 months for detection of relapse.
Tumor stage was based on the 6th American Joint Com-
mittee on Cancer criteria. Histologic grade was assessed
by the modified Bloom-Richardson classification. Dis-
ease-free survival (DFS) was measured from the date of
the first curative surgery to the date of the first locore-
gional or systemic recurrence, or death without any type
of relapse. Distant relapse-free survival (DRFS) was calcu-
lated from the date of the first operation to the date of dis-
tant metastasis or death without any type of relapse.
Overall survival (OS) was measured from the date of the
first surgery to the date of the last follow-up or death from
any cause.
Tissue Microarray
Formalin-fixed, paraffin-embedded tumor blocks were
arrayed using a tissue-arraying instrument (AccuMax
Array, Petagen, Inc., Seoul, Korea). On each H&E slide
of tumor block, invasive component was selected and a
corresponding area was marked on the surface of tumor
block. The designated zone of each donor block was
punched with a tissue cylinder and a core sample of 3 mm
in diameter with 3 to 5 mm in length was transferred to a
6  5 recipient block in a grid pattern. Normal breast tis-
sues entrapped within the block. Each core was assigned
with a unique TMA location number that was linked to a
database containing clinicopathological parameters.
Immunohistochemistry
TMA blocks were subjected to immunohistochemical
staining. Briefly, 5 lm-thick sections were obtained,
deparaffinized, and rehydrated. After treatment with 3%
hydrogen peroxide solution for 10 minutes to block
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endogenous peroxidase, the sections were pretreated in 10
mM citrate buffer for antigen retrieval in a microwave
oven for 20 minutes. After incubation with primary anti-
bodies against estrogen receptor (ER; SP1, 1:100; Thermo
Scientific, Fremont, Calif), progesterone receptor (PR;
PgR 636, 1:50; DAKO, Glostrup, Denmark), HER2
(polyclonal, 1:1,500; DAKO), and Ki-67 (MIB-1, 1:100;
DAKO), immunodetection was performed with biotinyl-
ated antimouse/rabbit immunoglobulin, followed by per-
oxidase-labeled streptavidin using a labeled streptavidin
biotin kit with 3,30-diaminobenzidine chromogen as a
substrate. Slides were counterstained with hematoxylin.
Tumors with 1% nuclear-stained cells were con-
sidered positive for ER and PR as the ASCO/CAP guide-
lines.15 The optimal cutoff for Ki-67 expression has not
been determined.16 We used an arbitrary value of 10% for
Ki-67 because the mean standard deviation (SD) of Ki-
67 was 9.4  11.1 among our whole study population.
HER2 staining was scored by counting the number of
cells positively stained on the membrane and expressed as
a percentage of total tumor cells according to the ASCO/
CAP guidelines13 using the following categories: 0, no im-
munostaining; 1þ, weak incomplete membranous stain-
ing in any proportion of tumor cells; 2þ, complete
membranous staining, either nonuniform or weak in at
least 10% of tumor cells; and 3þ, uniform intense mem-
branous staining in >30% of tumor cells. Tumors scored
as 0 or 1þ were considered to be IHC-negative, those
with 2þ were defined as IHC-equivocal, and cases scoring
3þwere considered IHC-positive.
FISH
FISH using PathVysion HER2 DNA Probe Kit (Abott,
Abott Park, III) was manually performed in all patients.
Briefly, consecutive sections from TMA blocks were
mounted on ProbeOn Plus microscope slides (Fisher Sci-
entific, Pittsburgh, PA), deparaffinized, and rehydrated.
Afterward, they were boiled for 10 minutes in pretreat-
ment solution, incubated with pepsin solution for 10
minutes, dehydrated in ethanol for 6 minutes, and finally
air dried. For hybridization, the buffered probe (HER2/
neu and centromere 17) was placed on the slide and pro-
tected by a coverslip that was sealed with rubber cement.
For denaturation, slides were heated to 82C and incu-
bated overnight at 45C in a dark humidified chamber.
The rubber cement and coverslip were then removed, and
the slides were transferred to stringent wash buffer for 10
minutes at 65C. Then, the slides were dehydrated in
ethanol for 6 minutes and air dried. Finally, they were
counterstained with 40,6-diamidino-2-phenylindole
(DAPI). Evaluation of signals was performed using an epi-
fluorescence microscope (Olympus, Tokyo, Japan)
equipped with a fluorescein, Cy3, and DAPI filter set and
a 100-Wmercury lamp. Counting was performed accord-
ing to the manufacturer’s manual. Signals were counted in
at least 60 invasive tumor nuclei each TMA cores. As the
ASCO/CAP guidelines,13 an absolute HER2 gene copy
number<4 or HER2 gene/chromosome 17 copy number
ratio (HER2/Chr 17 ratio) of<1.8 was considered FISH-
negative; an absolute HER2 gene copy number between 4
and 6 or HER2/Chr 17 ratio between 1.8 and 2.2 was
considered FISH-equivocal; and an absolute HER2 gene
copy number>6 or HER2/Chr 17 ratio>2.2 was consid-
ered FISH-positive. Lymphocytes, fibroblasts, and nor-
mal ductal epithelial cells were used as internal controls.
Statistical Analysis
The differences between the groups were evaluated by an
independent samples t-test in cases of continuous varia-
bles and by a chi-square test in cases of categorical varia-
bles. Fisher’s exact test was used when appropriate.
Survival curves were plotted using the Kaplan-Meier
method and group differences in survival time were
investigated by a log-rank test. A Cox hazards model was
used to identify variables that were independently
associated with survival. Logistic regression analysis was
employed to investigate parameters associated with
FISH-positivity in IHC-negative patients. All statistical
tests were 2 sided and P < .05 was considered significant.
SPSS version 17.0 (SPSS Inc., Chicago, IL) was used for
all statistical analyses.
RESULTS
Patient Characteristics and Comparison
of HER2 Results
The mean age at diagnosis and follow-up duration of 950
study population was 49.0 years (SD ¼ 10.4) and 71.2
months (SD ¼ 23.6), respectively. Patient characteristics
are presented in Table 1. Only 1 patient received weekly
adjuvant trastuzumab for 3 months due to financial bur-
den, and 12 (1.3%) received anti-HER2 therapy in the
metastatic setting regardless of HER2 results of this study.
IHC and FISH findings are summarized in Table 2.
Patients with IHC scoring 0, 1þ, 2þ, and 3þ were
20.4%, 41.8%, 20.9%, and 16.8%, respectively. FISH-
positivity was demonstrated in 24.2% of all cases. IHC
and FISH results matched in 97.4% of patients with IHC
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0, 95.2% of IHC 1þ, and 93.8% of IHC 3þ. Discrepan-
cies between IHC and FISH were observed in 2.6% of
patients with IHC 0, 4.8% of IHC 1þ, and 6.3% of IHC
3þ. When considering 751 IHC-negative or IHC-posi-
tive patients, overall concordance and discordance rates
between the 2 assays were 95.5% and 4.5%, respectively.
In patients with IHC 2þ, 71.9% did not amplify the
HER2 gene and 28.1% showed FISH-positivity.
Characteristics and Outcomes According to
Results of IHC and FISH
By analyses of characteristics according to IHC (data not
shown), IHC-positive patients were significantly associ-
ated with poorly differentiated tumors (P < .001), ER-
negativity (P < .001), PR-negativity (P < .001), and
higher proliferative index (P < .001). When cases were di-
vided into 2 groups as IHC-negative or IHC-equivocal
versus IHC-positive results, these statistical associations
were maintained similarly to analyses of 3 IHC subgroups.
DFS, DRFS, and OS according to IHC are demonstrated
in Figure 1A-C. IHC-positive patients showed a trend to-
ward poorer survival without statistical significance. When
patients were dichotomized into 2 groups as IHC 0, 1þ,
or 2þ versus IHC 3þ, DFS of IHC 3þ patients was sig-
nificantly poorer than that of IHC 0, 1þ, or 2þ cases (P
¼ .041). However, DRFS and OS between IHC-positive
patients and IHC-equivocal or IHC-negative cases were
not different (P ¼ .171 for DRFS, P ¼ .343 for OS).
Analyses of clinicopathological features according to
FISH determined that FISH-positive patients were signifi-
cantly associated with poorly differentiated tumors (P <
.001), ER-negativity (P< .001), PR-negativity (P< .001),
and higher proliferative index (P< .001), as shown in anal-
yses of IHC (data not shown). DFS, DRFS, and OS
according to FISH are shown in Figure 1D-F. FISH-posi-
tive patients were significantly related to poorer survival.
Characteristics and Survival According to
FISH Stratified by IHC Results
Patient characteristics according to FISH stratified by
IHC results are shown in Table 3. In IHC-negative
Table 1. Patient Characteristics
Factors Number %
Age (y)
Mean 6 SD 49.0  10.4
Median (range) 47.0 (20-87)
Type
Ductal 858 90.3
Lobular 25 2.6
Specified 67 7.1
Tumor stage
T1 450 47.4
T2 476 50.1
T3-4 24 2.5
Node stage
N0 508 53.5
N1 257 27.1
N2 116 12.2
N3 69 7.3
Grade
I 174 18.3
II 511 53.8
III 265 27.9
Estrogen receptor
Negative 257 27.1
Positive 693 72.9
Progesterone receptor
Negative 353 37.2
Positive 597 62.8
Ki-67
<10% 534 56.2
‡10% 415 43.7
Unknown 1 0.1
Type of surgery
Breast-conserving surgery 268 28.2
Total mastectomy 682 71.8
Radiotherapy
Not done 517 54.4
Done 433 45.6
Chemotherapy
Not done 152 16.0
Done 798 84.0
Endocrine therapy
Not done 316 33.3
Done 634 66.7
Anti-HER2 therapy
Not done 937 98.6
Done 13 1.4
Abbreviations: HER2, human epidermal growth factor receptor 2; SD,
standard deviation.
Table 2. Comparison of HER2 Results Between
Immunohistochemistry and Fluorescence In Situ
Hybridization
IHC Scoring FISH Total
(n 5 950, %)
Negative
(n 5 720, %)
Positive
(n 5 230, %)
0 189 (97.4) 5 (2.6) 194 (20.4)
1þ 378 (95.2) 19 (4.8) 397 (41.8)
2þ 143 (71.9) 56 (28.1) 199 (20.9)
3þ 10 (6.3) 150 (93.8) 160 (16.8)
Abbreviations: FISH, fluorescence in situ hybridization; IHC,
immunohistochemistry.
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patients, no difference in characteristics was observed
between FISH-negative and FISH-positive subgroups. In
IHC-equivocal patients, FISH-positive cases were signifi-
cantly associated with ER-negativity and PR-negativity.
In IHC-positive patients, FISH-positive subgroup was
significantly related to ER-negativity, PR-negativity, and
higher Ki-67 proliferative index. The mean  SD of per-
centage of ER, PR, and Ki-67 expression was 63.0 
26.5, 50.0  29.4, and 5.3 3.7 in IHC-positive/FISH-
negative cases and 32.0 34.8, 18.6  29.4, and 10.9 
7.6 in IHC-positive/FISH-positive cases, respectively
(P¼ .005, .001, and .023, respectively; t-test).
Survival according to FISH in patients with IHC-
negative, IHC-equivocal, and IHC-positive result is pre-
sented in Figures 2, 3, and 4, respectively. Among IHC-
negative patients, FISH-positive cases showed poorer
DFS, DRFS, and OS with borderline significance (Fig.
2). Among IHC-equivocal patients, FISH-positive sub-
groups were significantly associated with poorer DFS,
DRFS, and OS (Fig. 3). However, among IHC-positive
patients, there was no difference between FISH-negative
and FISH-positive cases (Fig. 4).
Multivariate analyses adjusted for FISH, age at diag-
nosis, tumor and nodal stages, grade, and ER in IHC-neg-
ative, IHC-equivocal, and IHC-positive patients are
shown in Tables 4, 5, and 6, respectively. In IHC-negative
patients, FISH-positivity was a significant factor for DFS,
but was not associated with DRFS and OS (Table 4). In
IHC-equivocal patients, positive FISH showed a negative
relationship with DFS, DRFS, and OS by Cox models
(Table 5). In IHC-positive patients, however, FISH was
not associated with outcomes (Table 6).
Factors Associated with Discordant HER2
Amplification in IHC-Negative Patients
Logistic regression model was applied to explore which
subgroup with IHC-negative result was associated with
HER2 amplification (Table 7). Of 591 IHC-negative
cases, 590 patients who had all parameters available were
analyzed with this model. Tumors with ER-positive,
grade II/III, and higher Ki-67 proliferative index had a
higher risk for discordant HER2 amplification. Age at di-
agnosis, tumor and node stages, and PR expression did
not increase the risk of FISH-positive results. Among our
dataset of IHC-negative patients, 8 (9.3%) of 86 patients
with ER-positive, grade II/III and Ki-67 10% demon-
strated discordantly FISH-positive results compared with
3 (2.4%) of 124 patients with ER-negative, grade II/III,
and Ki-67 10% (P ¼ .054, Fisher’s exact test) or 16
(3.2%) of 504 patients without having all these risk fac-
tors (P¼ .015, Fisher’s exact test).
Figure 1. Disease-free (A, D), distant relapse-free (B, E), and overall (C, F) survival according to results of human epidermal
growth factor receptor 2 (HER2) immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are shown.
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DISCUSSION
In real clinical situations, discordant results between IHC
and FISH have been demonstrated, and such cases may be
problematic. Unnecessary overtreatment may increase
side effects and costs without clinical benefits, whereas
undertreatment may affect patient’s outcomes. In previ-
ous reports, HER2 amplification was identified in 2%-
11% of patients with IHC 0 or 1þ and in 15%-48% of
those with IHC 2þ, and no amplification was observed in
5%-24% of cases with IHC 3þ.8-12 If HER2-positivity is
Figure 2. Disease-free (A), distant relapse-free (B), and overall (C) survival according to fluorescence in situ hybridization (FISH)
in immunohistochemistry-negative patients are shown.
Table 3. Characteristics According to Fluorescence In Situ Hybridization Stratified by Immunohistochemical Results
Factors IHC-Negative IHC-Equivocal IHC-Positive
FISH-Negative
(n 5 567)
FISH-Positive
(n 5 24)
Pa FISH-Negative
(n 5 143)
FISH-Positive
(n 5 56)
Pa FISH-Negative
(n 5 10)
FISH-Positive
(n 5 150)
Pb
Age (y) >.999
b .845 .486
£35 38 (6.7) 1 (4.2) 14 (9.8) 6 (10.7) 1 (10.0) 9 (6.0)
>35 529 (93.3) 23 (95.8) 129 (90.2) 50 (89.3) 9 (90.0) 141 (94.0)
Tumor stage .966 .875 >.999
T1 281 (49.6) 12 (50.0) 57 (39.9) 23 (41.1) 5 (50.0) 72 (48.0)
T2-4 286 (50.4) 12 (50.0) 86 (60.1) 33 (58.9) 5 (50.0) 78 (52.0)
Node stage .331 .303 .751
N0 317 (55.9) 11 (45.8) 65 (45.5) 30 (53.6) 6 (60.0) 79 (52.7)
N1-3 250 (44.1) 13 (54.2) 78 (54.5) 26 (46.4) 4 (40.0) 71 (47.3)
Grade .768 .076 .320
I/II 417 (73.5) 17 (70.8) 114 (79.7) 38 (67.9) 8 (80.0) 91 (60.7)
III 150 (26.5) 7 (29.2) 29 (20.3) 18 (32.1) 2 (20.0) 59 (39.3)
Estrogen
receptor
.152 .017 .005
Negative 144 (25.4) 3 (12.5) 24 (16.8) 18 (32.1) 0 (0.0) 68 (45.3)
Positive 423 (74.6) 21 (87.5) 119 (83.2) 38 (67.9) 10 (100) 82 (54.7)
Progesterone
receptor
.697 <.001 .002
Negative 187 (33.0) 7 (29.2) 36 (25.2) 29 (51.8) 1 (10.0) 93 (62.0)
Positive 380 (67.0) 17 (70.8) 107 (74.8) 27 (48.2) 9 (90.0) 57 (38.0)
Ki-67c .208 .193 .016
<10% 355 (62.7) 12 (50.0) 86 (60.1) 28 (50.0) 7 (70.0) 46 (30.7)
‡10% 211 (37.3) 12 (50.0) 57 (39.9) 28 (50.0) 3 (30.0) 104 (69.3)
Abbreviations: FISH, fluorescence in situ hybridization; IHC, immunohistochemistry.
a Chi-square test.
b Fisher’s exact test.
c Of 591 patients with IHC-negative result, 590 were available for Ki-67 expression.
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defined as the ASCO/CAP guidelines (Table 2), 216
(22.7%) patients in our study were determined to be
HER2-positive, which is consistent with previous
reports.3 When excluding IHC-equivocal cases, overall
concordance rates in our study were 95.5% between the 2
assays. These results were not significantly different from
earlier reports,8,10,11 confirming high concordance
between IHC and FISH.
Characteristics of IHC-positive patients were not
different from those of FISH-positive cases in the present
study. These features were poorly differentiation, ER-neg-
ativity, PR-negativity, and higher proliferative index as
widely known features of HER2-positive tumors.17 How-
ever, regarding prediction of prognosis, FISH more
clearly split survival outcomes with significance than IHC
interpretations classified into both 2 (0, 1þ, 2þ vs 3þ)
and 3 (0, 1þ vs 2þ vs 3þ) groups. These findings were
consistent with a previous study by Pauletti et al.18
Although our study was different from the 1 by Pauletti et
al18 with respect to patient characteristics, genetics of
study cohort (Asian vs South Australian), methodology
including used commercial antibody, and interpretation
criteria, taken together, FISH better predicts adverse out-
comes and is considered as ideal method for assessing
HER2.
It has not been clearly understood why protein over-
expression without gene amplification is documented or
gene amplification not being able to yield protein overex-
pression is possible. Several explanations have been sug-
gested mainly in the aspect of methodology and external
validation because IHC-positive/FISH-negative cases are
the majority of discordance.9,10,19 However, patients with
discrepancies between IHC and FISH may be associated
with potential biologic causes. These are chromosome 17
polysomy,20 dysregulated transcriptional activity,21 alter-
native splicing, which produces inhibitory isoforms,22
gene rearrangements affecting a part of HER2 epitope,12
altered stability of HER2 protein in tumor cells,23 and a
real intratumoral heterogeneity of HER2.24
Although equivocal IHC result should be validated
by FISH, it is still controversial whether FISH provides
additional information in IHC-negative or IHC-positive
cases. After stratification by IHC findings, we further
explored outcomes according to FISH. Among
Figure 3. Disease-free (A), distant relapse-free (B), and overall (C) survival according to fluorescence in situ hybridization (FISH)
in immunohistochemistry-equivocal patients are shown.
Figure 4. Disease-free (A), distant relapse-free (B), and overall (C) survival according to fluorescence in situ hybridization (FISH)
in immunohistochemistry-positive patients are shown.
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IHC-negative patients, FISH-positive cases showed poorer
DFS in univariate analyses and FISH positivity was a signif-
icantly negative prognostic factor when adjusted for other
clinicopathological variables. Our findings suggest that
FISHmight provide additional clinical implications on the
prediction of prognosis and another indication for anti-
HER2 therapy in a small minority of IHC-negative sub-
group. Actually the predictive significance of HER2 was
not able to be determined in the present study because
most our study cohort did not receive anti-HER2 therapy.
Although it is not yet determined whether trastuzumab
therapy works or improves survival in patients with IHC-
negative/FISH-positive or not, recent studies suggest FISH
identifies patients who are likely to benefit from trastuzu-
mab therapy.9,14 This hypothesis needs to be confirmed
through other dataset or new prospective clinical trials
because many trials have excluded IHC-negative patients at
the time of enrollment screening.
IHC-positive patients demonstrated no difference
in outcomes according to FISH. Nevertheless, these find-
ings did not determine that FISH did not provide any
information of IHC-positive cases. Because HER2 pro-
tein-overexpressed tumors without gene amplification are
associated with better clinicopathological features such as
Table 4. Multivariate Analyses in Immunohistochemistry-Negative Patients
Factors Disease-Free
Survival
Distant Relapse-Free
Survival
Overall survival
Hazard Ratio 95% CI Pa Hazard Ratio 95% CI Pa Hazard ratio 95% CI Pa
FISH (negative vs positive) 2.203 1.011-4.803 .047 1.789 0.774-4.136 .174 1.815 0.724 - 4.552 0.204
Age (35 vs >35) 0.566 0.300-1.069 .080 0.569 0.292-1.109 .098 0.609 0.301 - 1.232 0.167
Tumor stage (T1 vs T2-4) 1.870 1.170-2.988 .009 1.835 1.120-3.007 .016 1.816 1.045 - 3.155 0.034
Node stage (N0 vs N1-3) 2.608 1.659-4.100 <.001 2.930 1.806-4.754 <.001 2.687 1.594 - 4.531 <.001
Grade (I/II vs III) 1.108 0.671-1.829 .689 1.120 0.666-1.884 .668 1.059 0.608 - 1.845 0.838
ER (negative vs positive) 0.651 0.386-1.096 .106 0.658 0.383-1.130 .129 0.547 0.309 - 0.967 0.038
Abbreviations: CI, confidence interval; ER, estrogen receptor; FISH, fluorescence in situ hybridization.
a Log-rank test.
Table 5. Multivariate Analyses in Immunohistochemistry-Equivocal Patients
Factors Disease-Free Survival Distant Relapse-Free
Survival
Overall survival
Hazard Ratio 95% CI Pa Hazard Ratio 95% CI Pa Hazard ratio 95% CI Pa
FISH (negative vs. positive) 3.011 1.372-6.610 .006 3.011 1.296-6.991 .010 2.566 1.008-6.532 .048
Age (35 vs >35) 0.324 0.135-0.777 .012 0.343 0.133-0.887 .027 0.292 0.109-0.781 .014
Tumor stage (T1 vs T2-4) 1.561 0.697-3.498 .279 1.187 0.517-2.726 .686 1.572 0.585-4.223 .369
Node stage (N0 vs N1-3) 2.540 1.102-5.855 .029 3.464 1.350-8.885 .010 3.739 1.229-11.377 .020
Grade (I/II vs III) 0.374 0.136-1.029 .057 0.335 0.109-1.024 .055 0.441 0.142-1.369 .157
ER (negative vs positive) 0.808 0.348-1.879 .621 0.807 0.325-2.008 .645 0.436 0.171-1.111 .082
Abbreviations: CI, confidence interval; ER, estrogen receptor; FISH, fluorescence in situ hybridization.
a Log-rank test.
Table 6. Multivariate Analyses in Immunohistochemistry-Positive Patients
Factors Disease-Free
Survival
Distant Relapse-Free
Survival
Overall survival
Hazard Ratio 95% CI Pa Hazard Ratio 95% CI Pa Hazard ratio 95% CI Pa
FISH (negative vs positive) 0.757 0.221-2.592 .658 0.608 0.174-2.125 .436 0.624 0.136 - 2.855 .543
Age (35 vs >35) 1.263 0.298-5.358 .751 1.061 0.247-4.550 .936 1.623 0.215 - 12.235 .639
Tumor stage (T1 vs T2-4) 2.253 1.013-5.012 .046 3.105 1.238-7.789 .016 5.097 1.625 - 15.981 .005
Node stage (N0 vs N1-3) 1.497 0.717-3.123 .283 1.353 0.610-3.001 .457 1.217 0.508 - 2.912 .660
Grade (I/II vs III) 0.627 0.291-1.353 .234 0.727 0.319-1.658 .448 0.991 0.416 - 2.359 .984
ER (negative vs positive) 1.085 0.534-2.207 .821 1.207 0.550-2.650 .639 1.087 0.460 - 2.570 .849
Abbreviations: CI, confidence interval; ER, estrogen receptor; FISH, fluorescence in situ hybridization.
a Log-rank test.
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lower grade, higher hormone receptor expression, and
lower proliferative index, FISH might suggest a distinct
heterogeneity of HER2-positive breast cancers.21 Implica-
tions of FISH on the prediction of outcomes and respon-
siveness to anti-HER2 therapy in IHC-positive cases
remain to be determined.
From the viewpoint of cost-effectiveness, additional
FISH test might provide little benefits due to the very low
incidence of discrepancy, relatively high costs, and unpro-
ven efficacy of anti-HER2 therapy in IHC-negative/
FISH-positive patients.25,26 However, if a subgroup is
determined as having a higher probability of FISH-posi-
tivity among IHC-negative patients, additional FISH
may provide clinical benefits to those subgroups. Our
IHC-negative subgroup analyses showed that ER-positiv-
ity, grade II/III, and higher Ki-67 proliferative index were
associated with discordantly higher risk for HER2 gene
amplification. It was unexpected that ER-positivity was
associated with FISH-positivity because HER2 amplifica-
tion was significantly related to negative expression of ste-
roid hormone receptors. However, if considering FISH
result as the gold standard for determining HER2, undif-
ferentiation, and higher proliferation, our findings may
present undetermined heterogeneous characteristics of
luminal B molecular subtype. A clear immunohistochem-
ical definition of luminal B subtype is still being debated.
In addition to ER-positivity and/or PR-positivity, various
definitions such as HER2-positive,27 high grade,28 and
high Ki-67 proliferative index29 have been included in the
criteria for luminal B subtype. It is not clear whether aber-
rant HER2 signal pathways at transcriptional or transla-
tional levels induce luminal B subtype to amplify the
HER2 gene without protein overexpression. Further basic
or clinical research is necessary, and cost-effectiveness of
additional FISH test in IHC-negative cases should be
determined because economic burden of HER2 assays
and anti-HER2 therapy is different among nations.
Limitations of our study were TMA results could
not verify the identical results from whole sections, which
is the standard material for HER2 assays. Because 1 core
sample of tumor block was used, that may have impacted
interpretation of HER2 assays. Furthermore, the retro-
spective nature and different characteristics between pres-
ent study cohort and other population make our tentative
findings should be validated and replicated
independently.
In summary, IHC is highly concordant with FISH
in the assessment of HER2 status, and FISH better pre-
dicts prognosis of patients with invasive breast cancer.
However, a small number of discrepancies between the 2
assays are still reported and show different clinicopatho-
logical features and survival outcomes. As current clinical
guidelines, FISH assay should be recommended to IHC-
equivocal cases. Higher discordant HER2 gene amplifica-
tion is demonstrated in IHC-negative tumors showing
luminal B molecular subtype features of ER-positivity,
undifferentiation and higher Ki-67 proliferative index.
FISH test might be considered for a selected subgroup of
patients with IHC-negative result and additional clinical
benefits of FISH assay including the predictive signifi-
cance should be determined in those patients for improv-
ing outcomes.
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